Tech to Replace Animal Testing Is Almost Ready. Scientists Are Not

Advancements in organ-on-a-chip technology, such as the human lung-on-a-chip developed at Harvard’s Wyss Institute, are offering promising alternatives to traditional animal testing in pharmaceutical research. These microfluidic systems, which simulate human organ functions, have evolved from experimental prototypes to tools now recognized by regulatory bodies like the FDA. While these New Approach Methodologies (NAMs) demonstrate significant potential for drug development and toxicology, their widespread adoption faces substantial hurdles. Beyond the technical challenges of standardization and validation, the transition requires a fundamental shift in scientific culture, policy, and training. Experts note that while these systems are increasingly capable of outperforming animal models, the path toward replacing animal testing is complex, requiring rigorous head-to-head comparisons and a coordinated effort to update long-standing research practices across the global scientific community.